Mirum Pharmaceuticals, Inc. (MIRM) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 1 fund adding, and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $7.3M sold). Latest close $92.49 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.
RA Capital Management · Baker Bros. Advisors · Perceptive Advisors — 5 tracked funds hold MIRM. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 8 sales ($7.3M). Insider trading
AVALYN PHARMA INC (AVLN) · PARABILIS MEDICINES INC (PBLS) · Praxis Precision Medicines, Inc. (PRAX) · Aktis Oncology, Inc. (AKTS) · BIOCRYST PHARMACEUTICALS INC (BCRX) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| RA Capital Management | 0.32% | 318,554 | HELD Q3 filed Nov 16 |
| Baker Bros. Advisors | 0.26% | 445,975 | HELD Q3 filed Nov 16 |
| Perceptive Advisors | 0.20% | 115,391 | NEW Q3 filed Nov 16 |
| Polen Capital Management | 0.02% | 20,899 | ADDED (+1.8%) Q3 filed Nov 13 |
| Deerfield Management | 0.01% | 6,027 | NEW Q3 filed Nov 16 |
| Paradigm Biocapital Advisors | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -23.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 330 of 8,857 filers |
| Long-only filers among them | 327 |
| Change vs 2026 Q1 | +26 net · 320 entered · 294 exited |
| Shares reported, all filers | 71,453,786 |
| Reported value, all filers | $8.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $521.3M |
| Net income · FY2025 | $-23.4M |
| Total assets · FY2025 | $842.8M |
| Shares outstanding | 64,932,203 |
| Market cap (at latest close) | $6.0B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 6,663,045 |
| Share of shares outstanding | 10.26% |
| Days to cover | 7.30 |
Shares short at recent settlements — Jul 31, 2026: 6.8M · Aug 14, 2026: 6.5M · Aug 31, 2026: 6.2M · Sep 15, 2026: 6.3M · Sep 30, 2026: 7.0M · Oct 15, 2026: 6.7M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 72 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 27K · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 8 sales by 5 insiders ($7.3M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Ramasastry Saira | Sell | 2,000 | $92.28 | $184.6K | SEC filing | |
| Nov 11, 2026 | Brege Laura | Sell | 10,907 | $94.05 | $1.0M | SEC filing | |
| Nov 11, 2026 | Brege Laura | Sell | 3,260 | $94.74 | $308.9K | SEC filing | |
| Nov 4, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 20,000 | $90.00 | $1.8M | SEC filing |
| Sep 14, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell | 9,943 | $98.37 | $978.1K | SEC filing |
| Sep 2, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | Sell | 658 | $100.00 | $65.8K | SEC filing |
| Sep 1, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 8,312 | $98.08 | $815.2K | SEC filing |
| Sep 1, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 21,688 | $98.91 | $2.1M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | ERIC BJERKHOLT | Officer | 9,943 | $978.1K | Sep 14, 2026 | SEC filing |
| Sep 2, 2026 | JOLANDA MARIE HOWE | Officer | 658 | $65.8K | Sep 2, 2026 | SEC filing |
| Sep 1, 2026 | CHRISTOPHER PEETZ | Officer, Director | 30,000 | $3.0M | Sep 1, 2026 | SEC filing |
| Aug 18, 2026 | JOLANDA MARIE HOWE | Officer | 40,000 | $4.0M | Aug 18, 2026 | SEC filing |
| Aug 11, 2026 | ERIC BJERKHOLT | Officer | 6,001 | $599.5K | Aug 11, 2026 | SEC filing |
| Aug 10, 2026 | CHRISTOPHER PEETZ | Officer, Director | 20,000 | $2.0M | Aug 10, 2026 | SEC filing |
| Aug 3, 2026 | JOLANDA MARIE HOWE | Officer | 1,840 | $193.7K | Aug 3, 2026 | SEC filing |
| Jul 6, 2026 | CHRISTOPHER PEETZ | Officer, Director | 20,000 | $2.4M | Jul 6, 2026 | SEC filing |
| Jul 6, 2026 | ERIC BJERKHOLT | Officer | 5,000 | $611.3K | Jul 6, 2026 | SEC filing |
| Jul 1, 2026 | JOLANDA MARIE HOWE | Officer | 2,721 | $326.5K | Jul 1, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Jan 27, 2026 | SCHEDULE 13D/A | -8.8% (close Jan 28, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Jan 28, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | JANUS HENDERSON GROUP Ltd. | SC 13G/A | 5,909,184 | 9.7% | Jun 30, 2026 | SEC filing |
| Aug 6, 2026 | FMR LLC | SC 13G | 3,777,851.04 | 6.2% | Jun 30, 2026 | SEC filing |
| Apr 27, 2026 | BlackRock, Inc. | SC 13G/A | 3,465,559 | 5.7% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 17, 2026 | JANUS HENDERSON GROUP PLC | SC 13G/A | 6,065,308 | 11.8% | Dec 31, 2025 | SEC filing |
| Feb 13, 2026 | Eventide Asset Management, LLC | SC 13G/A | 2,093,582 | 4.1% | Dec 31, 2025 | SEC filing |
| Jan 27, 2026 | Frazier Life Sciences IX, L.P. | SC 13D/A | 3,566,912 | 5.9% | Jan 23, 2026 | SEC filing |
| Dec 5, 2025 | JANUS HENDERSON GROUP PLC | SC 13G/A | 5,445,039 | 10.6% | Nov 28, 2025 | SEC filing |
| Nov 14, 2025 | JANUS HENDERSON GROUP PLC | SC 13G/A | 4,997,586 | 10.0% | Sep 30, 2025 | SEC filing |
| Nov 14, 2025 | BIOTECHNOLOGY VALUE FUND L P | SC 13G/A | 772,595 | 1.5% | Sep 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 1 Lobbying Disclosure Act filings named this company as client, 2026–2026; most common issues: Health Issues (1).
Federal contracts: $459.6K in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $0 |
| FY2022 | $0 |
| FY2023 | $0 |
| FY2024 | $0 |
| FY2025 | $458.5K |
| FY2026 | $1.1K |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 36C25025P0648 | Department of Veterans Affairs | $231.7K | Jan 30, 2025 |
| 36C25025P1221 | Department of Veterans Affairs | $227.9K | Jun 10, 2025 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Distress Risk (Altman Z″) — Z″-Score: 0.54 · Working capital / assets: 0.41 · Retained earnings / assets: -0.79 · EBIT / assets: -0.03 · Equity / liabilities: 0.60
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2023 Q3, ranked #30 of 50.
Also held by the tracked funds that hold MIRM — ranked by lift, the co-holding pattern described in Methodology: AVALYN PHARMA INC (AVLN) · PARABILIS MEDICINES INC (PBLS) · Praxis Precision Medicines, Inc. (PRAX) · Aktis Oncology, Inc. (AKTS) · BIOCRYST PHARMACEUTICALS INC (BCRX) · Sionna Therapeutics, Inc. (SION) · ARROWHEAD PHARMACEUTICALS, INC. (ARWR) · Celcuity Inc. (CELC).
| Filed | Items | Source |
|---|---|---|
| Nov 10, 2026 | 8.01 Other Events | SEC filing |
| Nov 3, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 26, 2026 | 8.01 Other Events | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
AVALYN PHARMA INC (AVLN) · Track Record: how the signals scored · Practice timing on MIRM
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.